A Novel Strategy to Produce CAR ‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR /Cas9 and AAV
Cancer Medicine · 2026
DOI: 10.1002/cam4.71918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ruoyu Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Cell Therapy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Dependovirus, CRISPR-Cas Systems, Receptors, Chimeric Antigen, Receptors, Antigen, T-Cell, gamma-delta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)‐αβ T cells are commonly employed in tumor therapy but hindered by some limitations. γδ T cells are promising substrates for CAR therapy for their major histocompatibility complex (MHC)‐unrestricted recognition manner and innate immune function. Here, we established a novel method for generating CAR‐γδ T cells. We utilized the clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) (CRISPR/Cas9) method to interrupt the TCR delta chain constant region ( TRDC ) sequence, followed by the site‐directed insertion of the CAR sequence into the TRDC locus via homologous complementation mediated by adeno‐associated virus (AAV) gene delivery. We optimized electroporation parameters for Cas9/ribonucleoproteins (RNP) delivery and infection conditions for CAR‐gene carrying AAV in γδ T cells. These optimizations facilitated efficient TCR knockout and site‐directed CAR insertion, ultimately yielding functional CAR‐γδ T cells. In vitro experiments demonstrated that these newly prepared CAR‐γδ T cells could stimulate cytokine production, kill tumor cells as well as exhibit robust proliferative potential and memory‐like phenotype. These state‐of‐the‐art CAR‐γδ T cells could reduce tumor burden and extend the survival period of tumor‐bearing mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Cell Therapy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Department of Developmental Biology and Cancer, Great Ormond Street Institute of Child Health, University College London, London, UK.
ORCID-Profile: Xun Zeng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, R., Zhang, Y., Yuan, G., Yue, X., Ding, Y., Zeng, X., & Xiao, H. (2026). A Novel Strategy to Produce CAR ‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR /Cas9 and AAV. Cancer Medicine. https://doi.org/10.1002/cam4.71918
Vancouver
Dong R, Zhang Y, Yuan G, Yue X, Ding Y, Zeng X, et al. A Novel Strategy to Produce CAR ‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR /Cas9 and AAV. Cancer Medicine. 2026. doi:10.1002/cam4.71918
BibTeX
@article{Dong2026,
author = {Dong, Ruoyu and Zhang, Yixi and Yuan, Guangxun and Yue, Xiaoyan and Ding, Yingying and Zeng, Xun and Xiao, Haowen},
title = {A Novel Strategy to Produce CAR ‐γδ T Cells via Site‐Directed Gene Integration by a Combination of CRISPR /Cas9 and AAV},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71918}
}
EUVIMED